Chemomab Therapeutics (NASDAQ:CMMB) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Chemomab Therapeutics (NASDAQ:CMMB) issued its earnings results on Thursday. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18), Zacks reports.

Chemomab Therapeutics Stock Down 2.4%

Shares of CMMB traded down $0.04 during mid-day trading on Friday, reaching $1.66. 6,530 shares of the stock traded hands, compared to its average volume of 43,061. The stock has a fifty day simple moving average of $1.71 and a 200 day simple moving average of $1.94. Chemomab Therapeutics has a 12-month low of $1.35 and a 12-month high of $5.88. The firm has a market cap of $11.94 million, a price-to-earnings ratio of -0.75 and a beta of 0.51.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday, May 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $25.00.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. ADAR1 Capital Management LLC bought a new stake in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 80,000 shares of the company’s stock, valued at approximately $132,000. ADAR1 Capital Management LLC owned approximately 1.30% of Chemomab Therapeutics at the end of the most recent reporting period. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.